Li Li

TL;DR: This study reveals that the novel autophagy-suppressive circPARD3 promotes LSCC progression and chemoresistance through the PRKCI-Akt-mTOR pathway, providing new insights into circRNA-mediated autophagic regulation and potential biomarker and target for LSCC treatment.

TL;DR: Mechanistic studies revealed that circCORO1C competitively bound to let-7c-5p and prevented it from decreasing the level of PBX3, which facilitated the malignant progression of LSCC and may serve as a novel target for LSCC therapy.

TL;DR: Fascin actin-bundling protein 1 (FSCN1) as discussed by the authors is a highly conserved actin bundling protein that cross links F-actin microfilaments into tight, parallel bundles and is recognized as a candidate biomarker for multiple cancer types and as a potential therapeutic target.

TL;DR: In vitro and in vivo experiments demonstrate that SKA3 promotes LSCC cell proliferation and chemoresistance through a novel role of reprogramming glycolytic metabolism, providing a potential strategy for proliferation inhibition and chemosensitization in tumors, especially for LSCC patients with PLK1 inhibitor resistance.

TL;DR: In this paper, the clinical significance, function, and mechanism of miR-1207-5p in LSCC were investigated, and it was found that upregulation suppressed LSCC cell proliferation, invasion, migration, and xenograft tumor growth.